These listings are provided for informational purposes only. All arrangements to participate in a trial are between the client and the study group conducting the trial and does not involve the National MS Society, Arizona Chapter.
Clinical trials are studies to determine if a treatment is safe and effective for MS. These studies can offer people with MS an opportunity to actively participate in the effort to end the devastating effects of this disease - but these studies must be conducted carefully to ensure the validity of the results.
For more information about Clinical Trials click here.
Clinical Trials Available in Arizona
Agent: Teriflunomide Treatment Mode of Action: Safety/Efficacy Study Study Description/Purpose: A multi-center, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing MS who are treated wtih interferon-beta. Institution (s): Phoenix Neurological Associates; multiple sites nationwide Type of MS: RR Number of subjects: 1455 Enrollment Information: Lynne Flynn, CCRC lynneflynn@pnal.net
Agent: Ocrelizumab in Comparison to Interferon Beta-1a Treatment Mode of Action: Safety/Efficacy Study Study Description/Purpose: A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a in patients with relapsing MS. Institution (s): Phoenix Neurological Associates; multiple sites nationwide Type of MS: RR Number of subjects: 400 Enrollment Information: Lynne Flynn, CCRC lynneflynn@pnal.net
Agent: Ocrelizumab Treatment Mode of Action: Safety/Efficacy Study Study Description/Purpose: A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive MS. Institution (s): Phoenix Neurological Associates; multiple sites nationwide Type of MS: PPMS Number of subjects: 630 Enrollment Information: Lynne Flynn, CCRC lynneflynn@pnal.net
Agent: Aspirin
Treatment Mode of Action: To improve fatigue
Study Description/Purpose: Double-blinded, placebo-controlled study to evaluate safety, tolerability, and effectiveness of aspirin in improving fatigue in people with MS
Institution(s): Mayo Clinic, Scottsdale, Arizona; Mayo Clinic Rochester, MN; Mayo Clinic, Jacksonville, FL
Type of MS: RR, SP
Number of Subjects: 135
Funding: National MS Society
Enrollment Information: Teri Radam, radam.teresa@mayo.edu
Agent: Atacicept
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Multiple sclerosis occurs when the immune system attacks the brain and spinal cord. Increasing evidence indicates that immune cells known as “B cells” play a role in this attack. Early studies in lupus and arthritis diseases that also involve a misguided immune attack have shown some potential for benefit.
Institution(s): Sites in the United States are in Arizona, Michigan, New Hampshire, North Carolina, Ohio, Pennsylvania, and Tennessee.
Type of MS: Relapsing forms of MS
Number of Subjects: 292
Funding: EMD Serono, Inc.
Enrollment Information: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=388
Agent: BG00012 (oral dimethyl fumarate)
Treatment mode of action: To affect immune and nervous system function
Study Description/Purpose: Randomized, double-blinded, placebo-controlled study to determine safety and effectiveness
Institution(s): Multicenter, United States
Type of MS: RR MS
Number of Subjects: 1011
Funding: Biogen Idec
Enrollment Information: DEFINE@dandersoncompany.com
More Information
Agent: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis.
Study Two (CARE-MS II)
Study Description/Purpose: A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta‑1a (Rebifâ) in Patients with Relapsing‑Remitting Multiple Sclerosis Who Have Relapsed On Therapy
Institution(s): Northwest NeuroSpecialists, PLLC
Type of MS: RR
Number of Subjects: 1200
Funding: Genzyme Corporation, Bayer
Enrollment Information: Joan Laguna at 520-742-1833
Agent: Oral cladribine (Mylinax, Cladribine tablets, an agent that limits proliferation of immune cells) added on to Rebif® (interferon beta-1A)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Randomized, double-blind, placebo-controlled study to test safety and effectiveness of adding on Cladribine to Rebif, also known as the ONWARD study.
Institution(s): Multiple, worldwide
Type of MS: Relapsing forms
Number of Subjects: 260
Funding: EMD Serono, Inc.
Enrollment Information: Contact 1-888-275-7376 for more information about the ONWARD study.
Agent: Phase ll Cladribine Tablet Therapy with Interferon-beta (IFN-beta) Treatment
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Randomized, MD blind, placebo-controlled study to test safety and effectiveness of adding on Cladribine to Intreferon injections.
Institution(s): Mayo Clinic Arizona
Type of MS: Relapsing forms
Number of Subjects: 156
Enrollment Information: Contact Jan Light, (480) 301-8788
Agent: Interferon (IFN) B-1a weekly and glatiramer acetate (GA) daily
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blinded, randomized trial comparing interferon (IFN) B-1a weekly and glatiramer acetate (GA) daily alone or in combination
Institution(s): Mayo Clinic-Scottsdale, and others, North America
Type of MS: RR
Number of Subjects: 1000
Funding: NINDS
Enrollment Information: Jan Light, (480) 301-8788
Agent: Interferon (IFN) B-1a weekly and glatiramer acetate (GA) daily
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blinded, randomized trial comparing interferon (IFN) B-1a weekly and glatiramer acetate (GA) daily alone or in combination
Institution(s): Northwest Neurospecialists PLLC, and others, North America
Type of MS: RR
Number of Subjects: 1000
Funding: NINDS
Enrollment Information: Joan Laguna, (520) 742-1833
Agent: Laquinimod (oral)
Treatment Mode of Action: Antigen-specific immunologic tolerance
Study Description/Purpose: A randomized, double-blind, placebo-controlled study to evaluate safety and effectiveness in MS
Institution(s): Xenoscience, Inc.; Multiple, United States
Type of MS: RR
Number of Subjects: 1000
Funding: Teva Neuroscience
Enrollment Information: Chianti Smith, (602) 274-9500, csmith@xeonscience.com
Agent: Laquinimod (oral or IM)
Study Description/Purpose: A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of Interferon β-1a (Avonex®), in a rater-blinded design.
Institution(s): Northwest NeuroSpecialists, PLLC
Type of MS: RRMS
Number of Subjects: 400
Funding: Teva Neuroscience
Enrollment Information: Joan Laguna, 520-742-1833
Agent(s): Tysabri® (natalizumab)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: An open-label, single-arm, non-randomized study to evaluate effects on fatigue and cognition
Institution(s): Multiple, United States
Type of MS: Relapsing forms
Number of Subjects: 200
Funding: Biogen Idec
Enrollment Information: Please call MS Active Source, at (800) 456-2255, and ask for Medical Information.
Agent: Alemtuzumab vs. Rebif
Treatment Mode of Action: To affect immune function
Study Description/Purpose: A Phase 3 randomized, rater-blinded study comparing two annual cycles of intravenous Alemtuzumab to 3-times weekly subcutaneous Interferon Beta-1a (Rebif) in treatment-naïve patients with relapsing-remitting Multiple Sclerosis
Institution(s): Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center
Type of MS: RR
Number of Subjects: 525
Funding: Genzyme Corporation
Enrollment Information: Genzyme Medical Information, (800) 745-4447, medinfo@genzyme.com
Agent: Copaxone/Placebe, Avonex/Placebo, or Copaxone/Placebo
Treatment Mode of Action: Safety/Efficacy Study
Study Description/Purpose: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)
Institution(s): Barrow Neurological Clinics
Type of MS: RR
Number of Subjects: 1000
Funding: Mount Sinai School of Medicine
Enrollment Information: Breanna Bullock 602-406-6211
Agent: B600012 - fumerate
Treatment Mode of Action: Safety/Efficacy Study
Study Description/Purpose: A randomized, multicenter, placebo controlled and sctive comparator (GA) to evaluate efficacy and safety of BG00012 in subjects with RRMS.
Institution(s): Barrow Neurological Clinics
Type of MS: RR MS
Number of Subjects: 1232
Funding: Biogen Idec
Enrollment Information: Mary Catherine Thornton, mary.parker2@chw.edu
Agent: None
Treatment Mode of Action: Lifetime Observational Study
Study Description/Purpose: Large-Scale, Multi-Disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases
Institution(s): Barrow Neurological Clinics
Type of MS: Any
Number of Subjects: ---
Funding: Accelerated Cure Project for Multiple Sclerosis
Enrollment Information: Breanna Bullock, 602-406-6211
Agent: Participant Recruitment and Data Collection
Study Description/Purpose: Parental Involvement of Chronically Ill Mothers and Its Impact on the Child’s, participants will fill out a survey/questionnaire
Institution(s): The Graduate School and University Center (The Graduate Center), The City University of New York (CUNY)
Type of MS: All types
Number of Subjects: 120
Enrollment Information: Yung-Chi Chen, Email: ychen8@gc.cuny.edu, Phone: (917)365-7619
For Research Professionals
If you would like to include information about a clinical trial on this page, please download and complete the policies and application documents below.